Topic Editors

Department of Mechanical and Aerospace Engineering, School of Engineering and Applied Science, The George Washington University, Science and Engineering Hall, 800 22nd Street, NW, Washington, DC 20052, USA
Department of Mechanical and Aerospace Engineering, George Washington University, Washington, DC 20052, USA
Department of Mechanical & Aerospace Engineering, The George Washington University, Washington, DC 20052, USA

Advances in Low-Temperature Plasma Cancer Therapy

Abstract submission deadline
closed (20 June 2024)
Manuscript submission deadline
closed (20 September 2024)
Viewed by
1444

Topic Information

Dear Colleagues,

This topic will cover the most recent topics in the field of plasma cancer therapy. In the past two decades, low-temperature plasma cancer therapy has been proven to reflect promising effectiveness on many types of cancer cells in vitro and in vivo. Selectivity was also discovered that the normal cells and cancer cells respond differently to the plasma which can be used to minimize the side effects of the treatment. However, new active ingredients are discovered such as the radiofrequency emissions from the plasma, proving that plasma therapy is still not a fully understand cocktail. Therefore, the dose of plasma therapy is still unknown. On the other hand, since the plasma exposure to the open air can be disturbed by the environmental condition such as humidity and the target status such as the distance, control methods were also developed for the plasma generators to stabilize the treatments. This also leads to new low-temperature plasma generators such as plasma jet arrays to cover a larger treatment area, flexible DBD patches, and discharge tubes relying on physical effects only. Therefore, the frontiers in this field are clear, and we expect the following topics will be discussed soon.

Prof. Dr. Michael Keidar
Dr. Li Lin
Dr. Dayun Yan
Topic Editors

Keywords

  • plasma medicine
  • low-temperature plasma
  • atmospheric plasma
  • reactive oxygen species
  • reactive nitrogen species
  • plasma jet
  • DBD
  • cancer therapy

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cancers
cancers
4.5 8.0 2009 17.4 Days CHF 2900
Catalysts
catalysts
3.8 6.8 2011 13.9 Days CHF 2200
Current Oncology
curroncol
2.8 3.3 1994 19.8 Days CHF 2200
Plasma
plasma
1.9 2.3 2018 26.8 Days CHF 1400
Sci
sci
- 4.5 2019 37.1 Days CHF 1200

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers

There is no accepted submissions to this Topic at this moment.
Back to TopTop